Elijah Nazarzadeh and John Pritchard introduce Nebu~Flow – a novel class of nebuliser technology that represents a major step in the ability to deliver drugs efficiently to the lungs. overcoming the limitations of current systems and unlocking the potential of the inhalation route, including for systemic delivery.
Timo Kangastupa discusses the potential of the suprachoroidal space for highly effective, specifically targeted drug delivery to the choroid and retina, and how Visionisti’s technology simplifies and standardises the procedure, enabling the use of standard commercially available needles for suprachoroidal delivery.
Antonio Costa discusses the use of lipid nanoparticles in the modern drug delivery industry and introduces the DIANT system for the continuous processing of nanoparticles with integrated process analytical technology, which can provide the quality required for these injectable, complex formulations.
Brian Li, Jiunn-Ru Lai, Tsung-Chieh Cheng, Kuang-Hsiang Cheng, Min-Ru Wang, Chia-Chi Tina Feng, and Wen-Chi Huang introduce the company’s new engine for primary container injectors, the Primary Actuator, which targets the unmet needs in the autoinjector and wearable injector market as the market shifts towards large injection volumes.
Nicky Bertollo, Ronan Byrne and Andrew Muddle introduce Pharma Latch – a user-centric angled microneedle patch technology. They discuss its key benefits, such as dramatically increased payload potential, precision, low cost and variable patch-wear times, and highlight how Pharma Latch has the potential to overcome many of the limitations of existing routes of administration for therapeutics and vaccines.
Sarah Trenfield and Abdul Basit look at the potential applications of 3D-printing technology to create personalised drug therapies in fields such as multiple drug therapy and paediatric/geriatric care and introduce FabRx’s 3D-printing system, which can produce formulations to suit a variety of situations.